期刊
CANCER RESEARCH
卷 66, 期 13, 页码 6722-6731出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-05-3758
关键词
-
类别
资金
- Intramural NIH HHS [Z01 DC000016] Funding Source: Medline
- NIDCD NIH HHS [Z01 DC000016-12, Z01 DC 00016] Funding Source: Medline
We showed previously that the signal transcription factor nuclear factor-kappa B (NF-kappa B) is aberrantly activated and that inhibition of NF-kappa B induces cell death and inhibits tumorigenesis in head and neck squamous cell carcinomas (HNSCC). Thus, identification of specific kinases underlying the activation of NF-kappa B could provide targets for selective therapy. Inhibitor-kappa B (I kappa B) kinase (IKK) is known to activate NF-kappa B by inducing NH2-terminal phosphorylation and degradation of its endogenous inhibitor, I kappa B. Casein kinase 2 (CK2) was previously reported to be overexpressed in HNSCC cells and to be a COOH-terminal IKK, but its relationship to NF-kappa B activation in HNSCC cells is unknown. In this study, we examined the contribution of IKK and CK2 in the regulation of NF-kappa B in HNSCC in vitro. NF-kappa B activation was specifically inhibited by kinase-dead mutants of the IKK1 and IKK2 subunits or small interfering RNA targeting the 0 subunit of CK2. CK2 and IKK kinase activity, as well as NF-kappa B transcriptional activity, was shown to be serum responsive, indicating that these kinases mediate aberrant activation of NF-kappa B in response to serum' factor(s) in vitro. Recombinant CK2 alpha was shown to phosphorylate recombinant IKK2 as well as to promote immunoprecipitated IKK complex from HNSCC to phosphorylate the NH2-terminal S32/S36 of I kappa B alpha. We conclude that the aberrant NF-kappa B activity in HNSCC cells in response to serum is partially through a novel mechanism involving CK2-mediated activation of IKK2, making these kinases candidates for selective therapy to target the NF-kappa B pathway in HNSCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据